Create Account | Sign In: Author or Forum

 
 
News  |  Journals  |  Conferences  |  Blogs  |  Articles  |  Forums  |  Twitter    
 

 Headlines:

 

Category: Cardiology | Pharmacy | Rheumatology | Conference News

Back to Journal Articles

ACR: Mycophenolate Mofetil May Be Inferior to Azathioprine

Last Updated: November 09, 2010.

 

Less likely to prevent relapse in antineutrophil cytoplasmic antibody-associated vasculitis

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
Mycophenolate mofetil appears to be less effective than azathioprine for maintaining disease remission among patients with antineutrophil cytoplasmic antibody-associated vasculitis, according to a study published online Nov. 8 in the Journal of the American Medical Association to coincide with presentation at the annual meeting of the American College of Rheumatology, held from Nov. 7 to 11 in Atlanta.

TUESDAY, Nov. 9 (HealthDay News) -- Mycophenolate mofetil appears to be less effective than azathioprine for maintaining disease remission among patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV), according to a study published online Nov. 8 in the Journal of the American Medical Association to coincide with presentation at the annual meeting of the American College of Rheumatology, held from Nov. 7 to 11 in Atlanta.

Thomas F. Hiemstra, M.D., of the Cambridge University Hospitals NHS Foundation Trust in the United Kingdom, and colleagues randomized 156 patients with AAV to azathioprine (starting at 2 mg/kg/d) or mycophenolate mofetil (starting at 2,000 mg/d) after remission was induced with cyclophosphamide and prednisolone.

Over a median follow-up of 39 months, the investigators found that relapses were more common among patients in the mycophenolate mofetil group than among those in the azathioprine group (unadjusted hazard ratio, 1.69). Severe adverse events did not differ significantly between the mycophenolate mofetil and azathioprine groups. Outcome measures, including Vasculitis Damage Index, estimated glomerular filtration rate, and proteinuria, did not differ significantly between the two groups.

"Contrary to the hypothesis that mycophenolate mofetil is more efficacious than azathioprine without compromising patient safety, we have shown that mycophenolate mofetil is less effective than azathioprine for the prevention of relapses in AAV," the authors write. "Although mycophenolate mofetil may be considered in refractory cases, it should not be considered the first-line remission maintenance therapy in AAV."

Several authors disclosed financial ties to pharmaceutical companies, including Hoffman-La Roche, which provided reimbursement for study drugs.

Abstract
Full Text
Editorial
More Information

Copyright © 2010 HealthDay. All rights reserved.


Previous: Hospital Admission Delay in Non-STEMI Unchanged Next: Solar-Powered BP Device May Be Useful in Low-Income Areas

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

  • Ask a Doctor Teams: Respond to patient questions and discuss challenging presentations with other members.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.